BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8826561)

  • 1. Cisplatin nephrotoxicity in a patient with a single kidney.
    Udeani GO; Singh K; Mullane MR; Lad TE
    Ann Pharmacother; 1996; 30(7-8):782-6. PubMed ID: 8826561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity.
    Nisar S; Feinfeld DA
    Ren Fail; 2002 Jul; 24(4):529-33. PubMed ID: 12212833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
    Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
    Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
    Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
    Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of free creatine therapy on cisplatin-induced renal damage.
    Genc G; Okuyucu A; Meydan BC; Yavuz O; Nisbet O; Hokelek M; Bedir A; Ozkaya O
    Ren Fail; 2014 Aug; 36(7):1108-13. PubMed ID: 24845105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-induced human peripheral blood mononuclear cells' oxidative stress and nephrotoxicity in head and neck cancer patients: the influence of hydrogen peroxide.
    Quintanilha JCF; Visacri MB; Sousa VM; Bastos LB; Vaz CO; Guarnieri JPO; Amaral LS; Malaguti C; Lima CSP; Vercesi AE; Moriel P
    Mol Cell Biochem; 2018 Mar; 440(1-2):139-145. PubMed ID: 28828710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin.
    Henry CJ; Flesner BK; Bechtel SA; Bryan JN; Tate DJ; Selting KA; Lattimer JC; Bryan ME; Grubb L; Hausheer F
    J Vet Intern Med; 2018 Jan; 32(1):370-376. PubMed ID: 29080252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumor cisplatin nephrotoxicity in combined laser-induced thermal therapy for cancer treatment.
    Palumbo MN; Cervantes O; Eugênio C; Hortense FTP; Ribeiro JC; Paolini AAP; Tedesco AC; Sercarz JA; Paiva MB
    Lasers Surg Med; 2017 Oct; 49(8):756-762. PubMed ID: 28598516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
    Merouani A; Davidson SA; Schrier RW
    Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
    Dimery IW; Legha SS
    J Clin Oncol; 1986 Nov; 4(11):1670-6. PubMed ID: 3095503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of Cisplatin-induced nephrotoxicity.
    Suddek GM; El-Kenawi AE; Abdel-Aziz A; El-Kashef HA
    Chemotherapy; 2011; 57(4):321-6. PubMed ID: 21893983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of NADPH oxidase protects against cisplatin induced nephrotoxicity in mice by two step mechanism.
    Wang Y; Luo X; Pan H; Huang W; Wang X; Wen H; Shen K; Jin B
    Food Chem Toxicol; 2015 Sep; 83():251-60. PubMed ID: 26032634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine ratio of neutrophil gelatinase-associated lipocalin to creatinine as a marker for early detection of cisplatin-associated nephrotoxicity.
    Shahbazi F; Sadighi S; Dashti-Khavidaki S; Shahi F; Mirzania M
    Iran J Kidney Dis; 2015 Jul; 9(4):306-10. PubMed ID: 26174458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.
    Campbell AB; Kalman SM; Jacobs C
    Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery.
    Hakeam HA; Breakiet M; Azzam A; Nadeem A; Amin T
    Ren Fail; 2014 Nov; 36(10):1486-91. PubMed ID: 25155314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of rebamipide on cisplatin-induced nephrotoxicity in rats.
    Saad SY; Najjar TA; Al-Sohaibani MO
    Pharmacol Res; 2000 Jul; 42(1):81-6. PubMed ID: 10860639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin nephrotoxicity: symptomatic hypomagnesemia and renal failure.
    Gomez Campdera FJ; Gonzalez P; Carrillo A; Estelles MC; Rengel M
    Int J Pediatr Nephrol; 1986; 7(3):151-2. PubMed ID: 3804580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway.
    Wainford RD; Weaver RJ; Stewart KN; Brown P; Hawksworth GM
    Toxicology; 2008 Jul; 249(2-3):184-93. PubMed ID: 18583013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.
    Lee CK; Park KK; Hwang JK; Lee SK; Chung WY
    Phytother Res; 2009 Jul; 23(7):999-1005. PubMed ID: 19140122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.